Lpath Appoints Daniel L. Kisner, M.D. to Board of Directors http://finance.yahoo.com/news/lpath-appoints-daniel-l-kisner-123100059.html With his more than 30 years of experience with public and private companies focused on biopharmaceuticals, oncology, and biotechnology, Dr. Kisner will be a strong addition to our board, said Daniel H. Petree, Lpath's chairman. - As an independent member of the board and chair of a new board committee that will focus on advancing the drug candidates in our clinical and pre-clinical pipeline, we believe he will make important contributions as we move toward regulatory approval and commercialization of our proprietary and novel lipidomics-based therapeutics.